MX2022010657A - Anticuerpos conjugados con moleculas de acidos grasos y usos de los mismos. - Google Patents
Anticuerpos conjugados con moleculas de acidos grasos y usos de los mismos.Info
- Publication number
- MX2022010657A MX2022010657A MX2022010657A MX2022010657A MX2022010657A MX 2022010657 A MX2022010657 A MX 2022010657A MX 2022010657 A MX2022010657 A MX 2022010657A MX 2022010657 A MX2022010657 A MX 2022010657A MX 2022010657 A MX2022010657 A MX 2022010657A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- fatty acid
- acid molecules
- antibodies conjugated
- bsabs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Fats And Perfumes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen anticuerpos monoclonales (mAbs) o anticuerpos biespecíficos (bsAbs) o anticuerpos multi-específicos que comprenden una molécula de ácido graso (FA) conjugada con o cerca del dominio de unión a antígeno; se describen también ácidos nucleicos que codifican para los anticuerpos, composiciones que comprenden los anticuerpos, y métodos para producir los anticuerpos y el uso de los anticuerpos para tratar o prevenir enfermedades, tales como el cáncer y/o sus complicaciones asociadas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062982476P | 2020-02-27 | 2020-02-27 | |
PCT/US2021/019583 WO2021173783A1 (en) | 2020-02-27 | 2021-02-25 | Antibodies conjugated with fatty acid molecules and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022010657A true MX2022010657A (es) | 2022-09-23 |
Family
ID=77490164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022010657A MX2022010657A (es) | 2020-02-27 | 2021-02-25 | Anticuerpos conjugados con moleculas de acidos grasos y usos de los mismos. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20230089926A1 (es) |
EP (1) | EP4110398A1 (es) |
JP (1) | JP2023515196A (es) |
KR (1) | KR20220145854A (es) |
CN (1) | CN115279412A (es) |
AU (1) | AU2021226336A1 (es) |
BR (1) | BR112022013575A2 (es) |
CA (1) | CA3164646A1 (es) |
IL (1) | IL295413A (es) |
MX (1) | MX2022010657A (es) |
WO (1) | WO2021173783A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11434291B2 (en) | 2019-05-14 | 2022-09-06 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060099208A1 (en) * | 2004-11-08 | 2006-05-11 | Undurti Das N | Method of potentiating the therapeutic action of monoclonal and polyclonal antibodies |
US9493578B2 (en) * | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
BR112013000603A2 (pt) * | 2010-07-09 | 2016-07-05 | Jv Bio Srl | anticorpos conjugados com lipídios |
BR112016004242A8 (pt) * | 2013-08-28 | 2018-06-12 | Stemcentrx Inc | Métodos para conjugação sítio-específica de anticorpos e composições |
-
2021
- 2021-02-25 AU AU2021226336A patent/AU2021226336A1/en active Pending
- 2021-02-25 US US17/760,394 patent/US20230089926A1/en active Pending
- 2021-02-25 IL IL295413A patent/IL295413A/en unknown
- 2021-02-25 JP JP2022551581A patent/JP2023515196A/ja active Pending
- 2021-02-25 MX MX2022010657A patent/MX2022010657A/es unknown
- 2021-02-25 CA CA3164646A patent/CA3164646A1/en active Pending
- 2021-02-25 EP EP21760482.6A patent/EP4110398A1/en active Pending
- 2021-02-25 CN CN202180017893.9A patent/CN115279412A/zh active Pending
- 2021-02-25 KR KR1020227032067A patent/KR20220145854A/ko unknown
- 2021-02-25 BR BR112022013575A patent/BR112022013575A2/pt unknown
- 2021-02-25 WO PCT/US2021/019583 patent/WO2021173783A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL295413A (en) | 2022-10-01 |
EP4110398A1 (en) | 2023-01-04 |
CA3164646A1 (en) | 2021-09-02 |
JP2023515196A (ja) | 2023-04-12 |
AU2021226336A1 (en) | 2022-08-11 |
BR112022013575A2 (pt) | 2022-09-13 |
US20230089926A1 (en) | 2023-03-23 |
KR20220145854A (ko) | 2022-10-31 |
CN115279412A (zh) | 2022-11-01 |
WO2021173783A1 (en) | 2021-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020552010A1 (en) | Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof | |
MX2021007320A (es) | Moleculas agonistas de union al antigeno cd28 que actuan sobre el tumor. | |
CL2023002690A1 (es) | Anticuerpos anti-muc16-cd3 biespecíficos y conjugados anti-muc16-fármacos (divisional de 202102645) | |
PE20240218A1 (es) | Anticuerpos madurados por afinidad y humanizados para fcrh5 | |
PE20221262A1 (es) | Anticuerpos terapeuticos y sus usos | |
MX2022010657A (es) | Anticuerpos conjugados con moleculas de acidos grasos y usos de los mismos. | |
RU2016115866A (ru) | Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи | |
PE20181082A1 (es) | Constructos de anticuerpos para flt3 y cd3 | |
PE20190630A1 (es) | Anticuerpos de anti-tim-3 | |
PE20121542A1 (es) | Moleculas de anticuerpo anti-gcc y composiciones y metodos relacionados | |
PE20181952A1 (es) | Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos | |
AU2017297138A8 (en) | Anti-PD-1 antibodies, method for producing same and method for using same | |
AR100573A1 (es) | Anticuerpos anti-il-17, un método para producirlos y utilizarlos | |
CL2013003140A1 (es) | Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene. | |
AR091702A1 (es) | Anticuerpos anti-cd79b e inmunoconjugados | |
NZ623264A (en) | Sparc binding scfvs | |
MX2020011914A (es) | Anticuerpos anti-dll3 y usos de los mismos. | |
EA201990894A1 (ru) | Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения | |
PE20220392A1 (es) | Moleculas de union a claudina-6 y usos de las mismas | |
AR123480A1 (es) | Moléculas de unión terapéuticas | |
JP2020522280A5 (es) | ||
MX2022012628A (es) | Anticuerpos anti-phf-tau y usos de estos. | |
PH12020551187A1 (en) | Bispecific antigen-binding molecules and methods of use | |
MX2023011339A (es) | Anticuerpos anti-tau y usos de estos. | |
EA202092122A1 (ru) | Антитела против tip-1 и их применения |